• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Myelodysplastic syndromes - azacitidine

Azacitidine for the treatment of myelodyplastic syndrome, chronic myelomonocytic leukaemia, and acute myeloid leukaemia

Status:	History
Expected date of issue:	TBC
Referral date:	July 2008
Wave:	18
Process:	STA
Topic area: Cancer

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	Peter Littlejohns
Technical Lead:	Scott Goulden
Communications manager:	Alice Law
Project manager:	Jeremy Powell
Evidence review group:	West Midlands Health Technology Assessment Collaboration

Top

 

Provisional schedule

Closing date for invited submissions / evidence submission:	TBC
1st appraisal committee meeting:	01 July 2009
2nd appraisal committee meeting	03 September 2010
3rd appraisal committee meeting:	07 January 2010
4th appraisal committee meeting:	06 October 2010

Top

 

Consultees and commentators

Consultees Commentators (no right to submit or appeal) Manufacturers/sponsors Celgene (azacitidine) Patient/carer groups Leukaemia CARE Leukaemia Research Fund Leukaemia Society (UK) Macmillan Cancer Support MDS Patient Support Group Rarer Cancers Forum Professional groups British Committee for Standardisation in Haematology British Society for Haematology Cancer Research UK Royal College of Nursing Royal College of Pathologists Royal College of Physicians, Medical Oncology Joint Special Committee United Kingdom Oncology Nursing Society Others Department of Health Harrow PCT Stockton-On-Tees PCT Welsh Assembly Government General Department of Health, Social Services and Public Safety for Northern Ireland NHS Quality Improvement Scotland Comparator manufacturers Cephalon (doxorubicin) (CA&U not returned, not participating) Hospira UK (cytarabine, doxorubicin) (CA&U not returned, not participating) Pharmacia/Pfizer (cytarabine, doxorubicin) Schering Plough (doxorubicin) (CA&U not returned, not participating) Winthrop Pharmaceuticals UK/Sanofi Aventis (daunorubicin) Wockhardt UK (doxorubicin) (CA&U not returned, not participating) Zeneus (doxorubicin) (CA&U not returned, not participating) Relevant research groups None Evidence Review Group National Institute for Health Research Health Technology Assessment Programme West Midlands Health Technology Assessment Collaboration Associated Guideline Groups National Collaborating Centre for Cancer Associated Public Health Groups None

Top

 

Project history

Date Update 8 October 2009 The manufacturer has submitted substantial comments on the ACD and a Patient Access Scheme. The Committee has requested clarification from the manufacturer and this will be critiqued by the ERG and considered by the Committee on 3 November 2009. 22 July 2010 In line with the decision of the Appeal Panel, NICE will be seeking further information from MDS UK and from Celgene . This information will then be reviewed by an academic group before being considered by the Appraisal Committee.

Top

 

Key documents

Myelodysplastic syndromes - azacitidine: equality impact assessment 23 March 2011 Myelodysplastic syndromes - azacitidine: final appraisal determination 2 17 February 2011 Myelodysplastic syndromes - azacitidine: appraisal consultation 04 November 2010 Myelodysplastic syndromes - azacitidine: appeal decision 26 July 2010 Myelodysplastic syndromes - azacitidine: appeal announcement 01 June 2010 Myelodysplastic syndromes - azacitidine: notice of appeal 13 April 2010 Myelodysplastic syndromes - azacitidine: final appraisal determination 04 March 2010 Myelodysplastic syndromes - azacitidine: update to consultee and commentators 08 October 2009 Myelodysplastic syndromes - azacitidine: appraisal consultation 03 August 2009 Myelodysplastic syndromes - azacitidine: final matrix of consultees and commentators 29 January 2009 Myelodysplastic syndromes - azacitidine: final scope 29 January 2009 Myelodysplastic syndromes - azacitidine: comments on the draft matrix 29 January 2009 Myelodysplastic syndromes - azacitidine: draft matrix of consultees and commentators 29 January 2009 Myelodysplastic syndromes - azacitidine: comments on the draft scope 29 January 2009 Myelodysplastic syndromes - azacitidine: draft scope 29 January 2009

This page was last updated: 22 March 2011